In the interview, Dr. Pliszka emphasized that he and his associates “do not view cardiovascular side effects as a risk of the stimulants. The one group to be cautious with are those people that already have some pre-existing heart disease.”
He predicted that neuroimaging is going to lead ADHD research efforts in the future, but emphasized that, at this time, neuroimaging “shouldn't be used commercially to diagnose ADHD. The diagnosis is still made by the efforts of the physician talking to the family, talking to the child, and gathering data about behavior.”
Dr. Pliszka disclosed that he receives or has received research support, acted as a consultant, and/or serves on a speakers' bureau for Shire Pharmaceuticals Group, McNeil Pediatrics, and Eli Lilly & Co.
The document notes that there may be a place in ADHD treatment for medications not approved by the FDA. DR. PLISZKA